S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
Laser breakthrough could send stock soaring 2,467% (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
Laser breakthrough could send stock soaring 2,467% (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
Laser breakthrough could send stock soaring 2,467% (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
Laser breakthrough could send stock soaring 2,467% (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
NYSE:AMRX

Amneal Pharmaceuticals (AMRX) Stock Forecast, Price & News

$2.55
+0.04 (+1.59%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.44
$2.60
50-Day Range
$1.33
$2.57
52-Week Range
$1.24
$3.71
Volume
1.13 million shs
Average Volume
897,403 shs
Market Capitalization
$778.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.60

Amneal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
41.2% Upside
$3.60 Price Target
Short Interest
Healthy
4.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
20.00%
From $0.40 to $0.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

58th out of 980 stocks

Pharmaceutical Preparations Industry

22nd out of 485 stocks


AMRX stock logo

About Amneal Pharmaceuticals (NYSE:AMRX) Stock

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Stock News Headlines

Your Ultimate Investment Research Platform
MarketBeat All-Access is the all-in-one stock research solution that saves you time and helps you make more money. You get our top stock picks, best-in-class research tools, proprietary research reports and much more.
Amneal Pharmaceuticals (NYSE:AMRX) Shares Down 2.2%
Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 2.2%
Your Ultimate Investment Research Platform
MarketBeat All-Access is the all-in-one stock research solution that saves you time and helps you make more money. You get our top stock picks, best-in-class research tools, proprietary research reports and much more.
Amneal Pharmaceuticals (AMRX) Gets a Buy from Goldman Sachs
Q1 2023 Amneal Pharmaceuticals Inc Earnings Call
See More Headlines

AMRX Price History

AMRX Company Calendar

Last Earnings
5/05/2023
Today
6/04/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.60
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+41.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
-10.90%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$1.42 per share
Book Value
$0.44 per share

Miscellaneous

Free Float
224,325,000
Market Cap
$778.90 million
Optionable
Optionable
Beta
1.32

Key Executives

  • Chintu Patel
    Co-Chief Executive Officer & Director
  • Chirag K. PatelChirag K. Patel
    President & Co-Chief Executive Officer & Director
  • Anastasios G. Konidaris
    Executive VP, Chief Financial & Accounting Officer
  • Nikita ShahNikita Shah
    Chief Human Resources Officer & Executive VP
  • Andrew S. Boyer
    Chief Commercial Officer-Generics & Executive VP













AMRX Stock - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month price targets for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's share price to reach $3.60 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2023?

Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of 2023. Since then, AMRX stock has increased by 28.1% and is now trading at $2.55.
View the best growth stocks for 2023 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 6,220,000 shares, a decrease of 9.9% from the April 15th total of 6,900,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is currently 6.2 days. Approximately 6.3% of the company's stock are sold short.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our AMRX earnings forecast
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) posted its earnings results on Friday, May, 5th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $557.54 million for the quarter, compared to the consensus estimate of $555 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 107.13% and a negative net margin of 5.93%. During the same period in the previous year, the company posted $0.10 earnings per share.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, April, 21st. The company provided EPS guidance of $0.40-$0.50 for the period, compared to the consensus estimate of $0.50. The company issued revenue guidance of $2.25 billion-$2.35 billion, compared to the consensus revenue estimate of $2.31 billion.

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.38%), AQR Capital Management LLC (0.99%), State Street Corp (0.70%), Allspring Global Investments Holdings LLC (0.63%), Geode Capital Management LLC (0.62%) and Dimensional Fund Advisors LP (0.44%). Insiders that own company stock include Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $2.55.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $778.90 million and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

The company employs 7,600 workers across the globe.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.

This page (NYSE:AMRX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -